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Abstract Adsorbents designed with porosity which
allows the removal of protein bound and high molecular
weight uraemic toxins may improve the effectiveness of
haemodialysis treatment of chronic kidney disease (CKD).
A nanoporous activated carbon monolith prototype
designed for direct blood contact was first assessed for its
capacity to remove albumin bound marker toxins indoxyl
sulphate (IS), p-cresyl sulphate (p-CS) and high molecular
weight cytokine interleukin-6 in spiked healthy donor
studies. Haemodialysis patient blood samples were then
used to measure the presence of these markers in pre- and
post-dialysis blood and their removal by adsorbent recir-
culation of post-dialysis blood samples. Nanopores
(20–100 nm) were necessary for marker uraemic toxin
removal during in vitro studies. Limited removal of IS and
p-CS occurred during haemodialysis, whereas almost
complete removal occurred following perfusion through
the carbon monoliths suggesting a key role for such
adsorbent therapies in CKD patient care.
1 Introduction
Haemodialysis is a well-established, life sustaining therapy
for patients who progress to chronic kidney disease stage 5
(CKD5d) and do not receive a transplant. However mor-
bidity and mortality rates, particularly those associated
with cardiovascular disease (CVD) remain high despite
improved disease management and advances in high flux
and haemodiafiltration technology [1, 2]. The increase in
prevalence, rising costs and poor prognosis associated with
CKD5d are well established. Over 2 million CKD5 patients
are on dialysis worldwide with a prevalence rate rising by
5–8 % each year in developed countries in line with the
increasing incidence of diabetes, hypertension and obesity
[3–5]. Whilst less than 0.1 % of the European population
receive haemodialysis treatment, costs total 2 % of the
healthcare budget [6]. Despite the relatively high cost of
dialysis patient survival remains poor. Five year survival
data from the UK Renal Registry showed survival for
dialysis patients was marginally better than that for ovarian
cancer, but worse than that for colon cancer [7].
The pathophysiology linking CKD and CVD progres-
sion is multi-faceted but has a clear association with
chronic exposure of the endothelium to an inflammatory
and pro-atherogenic environment linked to chronic cyto-
kine expression and the action of protein bound and high
molecular weight uraemic toxins [8–15]. Current hae-
modialysis systems predominantly remove small, water
soluble metabolites and some low molecular weight pro-
teins through diffusion and convection but fail to remove
significant amounts those uraemic toxins whose retention
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might be most damaging. The current study used well
characterised high molecular weight cytokine interleukin 6
(IL-6) and protein bound indoxyl sulphate (IS) and p-cresyl
sulphate (p-CS) as marker molecules for this group. Raised
IL-6 is a predictive marker for all cause and CVD related
morbidity and mortality in CKD patients [16]. IS (213 Da)
and p-CS (188 Da)are small molecules derived from gut
bacterial metabolism of dietary proteins but are predomi-
nantly non-covalently bound in the plasma to 66 kDa
albumin and are therefore poorly removed by haemodial-
ysis. Both are instigators of sustained oxidative stress with
subsequent, adverse effects on cardiovascular, renal and
bone physiology and are considered prime targets for
removal through sorbent based strategies [17–23].
Examples of sorbent containing extracorporeal devices
include the molecular adsorbent regenerating system
(MARSTM), fractionated plasma separation and adsorption
system (PrometheusTM) and Hemocleanse SSR [24, 25].
MARS and Prometheus have both been designed for the
treatment of liver failure where HD alone is ineffective in
bridging to liver regeneration or transplant. MARS con-
tains a microporous activated carbon column and works by
dialysing patient blood across an albumin impermeable
high flux membrane into an albumin rich dialysate. The
dialysate is then regenerated by filtration through a low flux
dialysis membrane, a microporous activated carbon column
and an anion exchange resin column. The Prometheus
system contains two adsorber cartridges and takes a dif-
ferent approach in which albumin and toxins both pass
across an albumin permeable, 250 kDa cut-off membrane
and albumin bound toxins are then removed in a secondary
circuit by filtration through a neutral resin adsorber fol-
lowed by an anion exchanger. The water soluble toxins are
removed by blood filtration through a second high flux
dialyzer. The Hemocleanse device also contained activated
microporous carbon, and was used in the treatment of acute
hepatic decompensation. However none of these devices
have substantially improved patient outcomes compared to
standard supportive medical management.
Haemoperfusion systems using microporous activated
carbon were tested for the treatment of kidney failure more
than 40 years ago and showed significant efficacy but
technical problems with release of fine carbon particles,
clotting, electrolyte imbalance and platelet loss limited
further development [26–28]. To improve haemocompati-
bility most activated carbon adsorbents in current clinical
use tend to be coated with cellulose or hydrogel/heparin co-
polymers [29]. Unfortunately, such coatings also limit
adsorptive capacity for high molecular weight molecules
and the only carbon haemoadsorbents used clinically in the
European Union for direct blood contact are those for the
treatment of severe drug overdose [30]. Recent advances in
carbon technology have allowed the development of a
novel phenolic resin derived activated carbon, which can
be used uncoated for direct contact with blood and has a
tailored nanoporous structure allowing adsorption of larger
biological toxins above 50 kDa [31–33]. A three dimen-
sional extruded carbon monolithic block can be made with
straight transport channels along its length so that adsorp-
tion occurs by direct blood contact. We have previously
reported that these activated carbons do not activate com-
plement or adsorb clotting factors to alter intrinsic or
extrinsic clotting cascades [31, 34]. This study was a proof
of concept study designed firstly to measure the impact of
monolith porosity on the removal of selected marker
uraemic toxins using in vitro methods. Following demon-
stration of marker molecule removal, a pilot study using
clinical haemodialysis patient blood samples was then
undertaken to establish whether these representative urae-
mic toxins remain in blood after standard haemodialysis
treatment and can then be removed following adsorbent
monolith haemoperfusion.
2 Materials and methods
2.1 Material synthesis and physical characterisation
of porosity
Monolith adsorbents were synthesised by MAST Carbon
International Ltd (Basingstoke, UK).The monoliths used
were 0.7 cm wide and 10 cm long and contained 32
channels running along the length of the monolith, each
with a width of 0.5 mm. Monoliths were formed by mixing
and curing varying formulations of Novalac resin, ethylene
glycol and hexamine. The resulting resin cake was crushed,
dried or washed to remove excess pore former, milled to
form a dough and then extruded. The resulting monoliths
were carbonised and activated in carbon dioxide at tem-
peratures of up to 900 C with the nanoporosity controlled
primarily by initial resin pore-former composition. The
porosity of the resultant materials was characterised by
scanning electron microscopy (SEM) using a Sigma field
emission gun (FEG)-SEM microscope (Carl Zeiss NTS,
Cambridge, UK) and by porosimetry using an Autosorb gas
sorption analyser and an automatic PoreMaster mercury
intrusion porosimeter (Quantachrome Instruments Ltd,
Hook, UK). Calculations relating to surface area, pore
volume and pore size distribution were carried out using
Quantachrome software.
2.2 In vitro studies to measure adsorption of IS, p-CS
and IL-6 by monoliths with varying porosity
The ability of adsorbent monoliths to remove marker
uraemic toxins was measured using healthy donor blood
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spiked with p-CS (250 lM), IS (125 lM) and IL-6
(1,000 pg/ml). A continuously circulating system was used
to compare uraemic toxin removal from plasma and blood
by monoliths of varying porosity. A 20 ml reservoir vol-
ume of spiked blood was circulated through each monolith
pre-wetted with phosphate buffered saline (PBS) at a rate
of 5 ml/min and samples were taken at timed intervals.
Blood samples were centrifuged at 3,500 rpm for 15 min
and plasma was removed. All samples were stored at
-20 C prior to analysis.
2.3 HPLC analysis of IS and p-CS adsorption
The HPLC method was adapted from that described by de
Loor et al. [35] using competitive albumin binding with
sodium octanoate to measure total p-CS and IS in plasma.
Plasma (200 ll) was incubated with 250 ll of sodium
octanoate (0.24 lM) for 30 min. Internal standard (naph-
thalene sulphonic acid, 0.5 mM, 20 ll) was added. Sam-
ples were mixed with 2 ml of ice cold acetone to
precipitate proteins and centrifuged for 10 min at
4,000 rpm. Supernatant was removed, mixed with 2 ml ice
cold dichloromethane and centrifuged for 10 min at
4,000 rpm. The top aqueous phase was removed and 40 ll
of 1 M HCl was added to stabilise the solution. Peak
separation was achieved using a Fortis C18 (150 mm 9
4.6 mm OD, 3 lM) column fitted with a 0.5 lm fritted
Krudkatcher pre-cartridge. The column was maintained at
25 C. Shell vials containing the samples, within spring-tip
inserts, were placed in a Waters 717 plus autosampler at
15 C which was set for a 10 ll injection, 20 min run time
and 10 min report delay. A Perkin Elmer Series 200 qua-
ternary gradient pump was programmed to deliver the
mobile phases [A (%) = 0.2 % trifluoroacetic acid (TFA)
in water, B (%) = 0.2 % TFA in acetonitrile as follows:
85/15 (hold 5 min)–80/20 (5 min)–0/100 (2 min, hold
3 min) at 0.6 ml/min, then 85/15 (2 min) at 1.0 ml/min]. A
Varian Prostar 363 fluorescent detector was employed with
a time programme. Dual detection wavelengths were used.
IS and internal standard were detected initially at excitation
and emission wavelengths of 280 and 360 nm, respec-
tively. Detection of p-CS was accomplished at excitation
and emission wavelengths of 260 and 296 nm, respec-
tively. Peaks were visualised and integrated using Total-
chrom software via a PE Nelson 900 Series (A–D)
interface. Limits of detection (LOD) and quantification
(LOQ) were calculated using the following equations.
LOD ¼ 3:3  r
S
;
LOQ ¼ 10  r
S
;
where S is the slope of the calibration curve and r is the
standard deviation of the response based on the calibration
curve.
2.4 ELISA analysis of IL-6 adsorption
Plasma samples from the adsorption studies underwent a 1
in 25 dilution in assay diluent and were analysed by ELISA
according to manufacturer’s instructions (BD Biosciences,
Oxford, UK). Plasma samples from the clinical sampling
study were analysed by ELISA for IL-6 content without
undergoing further dilution.
2.5 Pilot study using haemodialysis patient blood
samples to assess small prototype device efficacy
A small proof of concept study was conducted using hae-
modialysis patient blood samples. Ethical approval for the
study was obtained from the National Research Ethics
Committee for the South East Coast—Brighton and Sussex
REC reference 11/H1111/7. Eleven patients receiving
haemodialysis at the Sussex Kidney Unit were recruited to
the study using an approved informed consent protocol.
The patients underwent a standard 4 h, thrice weekly
haemodialysis regime, using a high flux FX-10 polysulfone
haemodialyser. Blood was drawn before and after hae-
modialysis for measurement of urea, creatinine, calcium,
total protein, albumin, haemoglobin, leukocyte, erythro-
cyte, platelet count, IS, p-CS and IL-6. An additional 20 ml
of post-dialysis patient blood was collected into heparin-
ised tubes (16 IU/ml blood) and perfused through a nano-
porous carbon monolith in a continuously circulating
system for 90 min. Blood in this system was analysed at 0,
30, 60 and 90 min to assess removal of IS, p-CS, IL-6 and
fibrinogen following perfusion through the monoliths over
time. After 90 min blood was again analysed for changes in
urea and other parameters listed above following monolith
recirculation. Plasma was isolated by centrifugation at
3,500 rpm for 15 min and was stored at -20 C prior to
analysis by HPLC, ELISA and coagulometry. Changes in
fibrinogen concentration were measured using a START 4
coagulometer and Fibri-prest kit using a 1:20 dilution of
plasma samples (Diagnostica Stago, Theale, UK).
2.6 Statistics
Data from in vitro studies was analysed for statistical sig-
nificance using Student’s t test comparing monolith filtra-
tion versus control groups at 60 min. Data from the pilot
study was analysed for statistical significance using Stu-
dent’s t test comparing paired data before and after hae-
modialysis and before and after monolith filtration. Data is
J Mater Sci: Mater Med (2014) 25:1589–1597 1591
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expressed as the mean value ± the standard error of the
mean (s.e.m).
3 Results
3.1 Characterisation of adsorbent porosity
The pore size distribution plots derived from mercury po-
rosimetry showed differences in the porosity of the
monoliths made of different resin and pore former com-
binations. Two types of carbon monolith were used for the
in vitro study. The nanoporous monoliths had pores in the
mesoporous to small macroporous range with a diameter of
2–100 nm (Fig. 1a). The microporous activated carbon
monoliths had pores of less than 2 nm only. Nitrogen gas
porosimetry data analysis indicated a surface area of
852 m2/g and a pore volume of 1.14 cc/g for the meso-
porous monoliths and a surface area of 782 m2/g and pore
volume of 0.51 cc/g for the microporous monoliths.
Nanoporous domains were visible on the high magnifica-
tion scanning electron micrographs taken of transverse
sections of the nanoporous activated carbon monoliths
(Fig. 1b).
Fig. 1 Characterisation of nanoporous monolith porosity was carried
out using PoreMaster mercury intrusion porosimetry and Sigma field
emission gun-scanning electron microscopy (FEG-SEM) a Quanta-
chrome data reduction software was used to calculate a mercury pore
size distribution plot showing nanoporous domains of 2–100 nm
within the prototype carbon monoliths. The second peak is produced
by interparticulate spaces which are 1–10 microns in diameter. b An
SEM micrograph of a transverse section of the nanoporous activated
carbon monolith showed internal nanoporous domains (magnification
9100,000)
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Fig. 2 a IL-6, b indoxyl sulphate and c p-cresyl sulphate remaining
following filtration of spiked fresh human blood through nanoporous
monoliths, microporous monoliths and spiked and non-spiked
controls (n = 3, mean ± s.e.m.). Filled star P \ 0.01 for concentra-
tion of IL-6, IS, p-CS remaining following monolith filtration
compared to the positive control of spiked blood circulated without
a monolith at each time point
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3.2 In vitro studies of IL-6, IS and p-CS adsorption
by monoliths with varying porosity
The in vitro monolith recirculation studies revealed a sig-
nificant reduction in IL-6 concentration after 15 min of
continuous filtration through the nanoporous monoliths
(Fig. 2a, P \ 0.01). IL-6 concentration was reduced from
900 to 400 pg/ml over the 60 min filtration cycle. In con-
trast, filtration through the microporous monoliths pro-
duced little reduction in the concentration of IL-6. Some
removal of IS and p-CS occurred following continuous
perfusion of spiked whole blood through the microporous
carbon monoliths. The concentration of IS and p-CS were
reduced from 120 to 60 lM and from 275 to 150 lM
respectively. However, the reduction in concentration was
greatest following perfusion through the nanoporous
monoliths. IS concentration was reduced from 140 to
20 lM and p-CS was reduced from 350 to 75 lM (Fig. 2b,
c). Only the nanoporous monoliths removed significant
amounts of the high molecular weight cytokine IL-6. The
albumin bound uraemic toxins IS and PCS were removed
to some extent by microporous carbons but removal was
much more effective following perfusion through the
nanoporous carbon monoliths. The nanoporous monoliths
were therefore used to conduct the pilot study using post
haemodialysis blood samples.
3.3 Pilot study using haemodialysis patient blood
samples to assess small prototype device efficacy
High concentrations of IS and p-CS were detected in all
haemodialysis patient blood samples prior to dialysis. An
insignificant reduction in IS and p-CS occurred following
standard high flux haemodialysis (Fig. 3a, b) (P [ 0.01).
However, after 30 min of continuous perfusion of the post
high flux haemodialysis patient blood samples through the
nanoporous carbon monoliths the concentration of both had
decreased to negligible levels (Fig. 3) (P \ 0.01).Raised
levels of IL-6 were present in only one of the monolith
filtration group blood samples (patient 3, Table 1) and one
of the control group samples using dialysis patient blood in
a sham circuit without monolith (patient 10, Table 1). The
IL-6 concentration was reduced by 50 % following carbon
monolith filtration but was not reduced in the control group
sample (Table 1).
Changes in blood biochemistry pre-dialysis, post-dialy-
sis, post monolith filtration and following filtration through
the system without a monolith in place are shown in
Table 2. No significant difference in post monolith perfu-
sion levels occurred when compared to control levels for
all of the markers except for creatinine and total protein.
Creatinine levels dropped from a mean value of
647 ± 190 lM to 256 ± 61 lM post haemodialysis. A
significant reduction in creatinine levels to 37 ± 16 lM
occurred following monolith filtration (P \ 0.01) in con-
trast to the control group where levels remained unchanged
(Table 2). The total protein levels dropped to just below
normal range when compared to the control group
(P \ 0.01). The platelet count was reduced in both the
monolith perfusion and control groups (P [ 0.01) indicat-
ing that the reduction occurred as a result of blood perfu-
sion through an extracorporeal circuit but not as a direct
result of monolith contact (Table 2). No significant dif-
ference in fibrinogen concentration was observed in the
carbon monolith filtration samples when compared to the
controls (P \ 0.01, Fig. 4).
4 Discusssion
Protein bound, middle and high molecular weight uraemic
toxins accumulate during the progression of CKD and are
poorly removed by current haemodialysis treatments. Our
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Fig. 3 The concentration of a indoxyl sulphate (IS) and b p-cresyl
sulphate (p-CS) remaining in dialysis patient blood samples pre-
dialysis, post-dialysis and then after 30, 60 and 90 min filtration
through the nanoporous carbon monoliths (n = 7) or tubing only
controls (n = 4).Monolith filtration was carried out on 20 ml blood
samples taken from patients post-dialysis. #P [ 0.01 for pre-dialysis
versus post dialysis levels of IS and p-CS. Filled star P \ 0.01 for
pre-dialysis compared to post-monolith filtration levels of IS and
P = 0.01 for pre-dialysis compared to post-monolith filtration levels
of p-CS
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study has demonstrated that activated carbon monoliths
with a large surface area for adsorption can be selectively
tailored to contain nanoporous domains of up to 100 nm
which are capable of adsorbing high molecular weight and
protein bound uraemic toxins. In this way the activated
carbon used here differs by the addition of nanopores
from the microporous ‘charcoals’ used in previous
extracorporeal studies. Our nanoporous monoliths are
derived from synthetic precursors allowing a more con-
sistent product profile and removing the propensity for fine
carbon particle release. The monolith structure itself is also
unique in an extracorporeal device and allows direct blood
flow along straight channels within an extruded carbon
block. Although a higher surface area for adsorption per
gram of carbon could be gained from a packed carbon bead
system the monolithic structure allows blood to flow
without a significant pressure drop across the system. We
have previously reported in vitro studies which showed
improved biocompatibility of these nanoporous monoliths,
observing that complement was not activated, and similarly
clotting factors were not consumed [31, 34].
We sought first to establish what porous characteristics
were necessary to ensure adsorption of high molecular
weight cytokine IL-6, and protein bound p-CS and IS from
spiked human blood. Our in vitro study confirmed the
importance of specifically tailored nanoporous domains of
2–100 nm for the removal of high molecular weight mol-
ecules such as IL-6 and the complex mechanisms involved
in carbon adsorbent binding of protein bound molecules.
The monoliths with pores of up to 100 nm targeted both
high molecular weight and protein bound species unlike the
Table 1 Measurement of IL-6 concentration (pg/ml) in blood
samples taken from haemodialysis patients pre-dialysis, post dialysis
and after 90 min perfusion of post-dialysis patient blood samples
through a nanoporous carbon monolith (patient 1–7) or the no
monolith control (patient 8–10). Significantly raised levels of IL-6
were detected in only one of the monolith (patient 3) and 1 of the
control group samples (patient 10)
Patient 1 2 3 4 5 6 7 8 9 10
Pre-dialysis IL-6 (pg/ml) \10 \10 72 \10 \10 \10 \10 14 0 421
Post dialysis IL-6 (pg/ml) \10 \10 125 0 \10 \10 \10 \10 0 435
Post monolith or control IL-6 (pg/ml) 0 \10 53 0 0 0 0 \10 0 431
Table 2 Changes in key blood parameters following nanoporous monolith filtration of post-haemodialysis patient blood samples compared to
the no monolith controls
Monolith (n = 7, mean ± SD) control (n = 4, mean ± SD)
Normal range Pre-dialysis Post
dialysis
Post monolith
filtration
Pre-dialysis Post-dialysis Post control
filtration
Urea 1.7–8.3 mmol/L 20.8 ± 7.6 6.5 ± 2.7 4.6 ± 1.8 18.5 ± 4 6.25 ± 1.2 6.65 ± 2
Creatinine 62–106 lmol/L 647 ± 190 255.6 ± 61 37 ± 16a 928 ± 247 373 ± 112 373 ± 112
Adjusted calcium 2.15–2.55 mmol/L 2.27 ± .2 2.4 ± .3 1.98 ± .3 2.2 ± .09 1.9 ± .05 1.9 ± .05
Total protein 66–87 g/L 65.7 ± 6.5 75 ± 4 56 ± 36a 65.75 ± 2.8 68.25 ± 2.6 68.2 ± 5.5
Albumin 34–48 g/L 39.3 ± 4 45.6 ± 4 34.7 ± 2.9 40.5 ± 1.73 41 ± 1.4 39.5 ± 2.6
HB 13.5–18 g/dL 11.6 ± .7 12.8 ± .55 9.9 ± 2.03 10.9 ± 1.2 11 ± 1 11.8 ± 4.3
WBC 4–11 9 10*9/L 73 ± 164 7 ± 2.9 7.2 ± 2.9 6.4 ± 1.6 6.35 ± 1 5.8 ± 2.4
Platelet 150–450 9 10*9/L 188 ± 96 203.7 ± 1.9 142.9 ± 108 195 ± 38 185 ± 11 116 ± 44
RBC 4.5–6.5 9 10*12/L 3.8 ± .5 4.2 ± .4 3.2 ± 0.65 3.4 ± .2 3.5 ± 2 3.6 ± 1.3
HCT 0.4–.54 fL .35 ± .03 .38 ± .02 .3 ± .06 .3 ± .04 .34 ± .03 .34 ± .1
a Only creatinine and total protein were reduced to below normal levels compared to the no monolith controls
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Fig. 4 The concentration of fibrinogen measured in dialysis patient
blood samples pre-dialysis, post-dialysis and after 30, 60 and 90 min
filtration through the nanoporous carbon monoliths (n = 5) or
controls (n = 4). P [ 0.01 for monolith filtration versus control
sample concentration of fibrinogen
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monoliths made from standard microporous carbons which
showed negligible removal of IL-6. Some removal of the
protein bound IS and p-CS occurred but adsorption was
much less than that achieved by the nanoporous monoliths.
In the second part of the study, using pre and post
haemodialysis patient blood samples, IS and p-CS were
detected in high concentrations both pre- and post-hae-
modialysis and were then reduced to negligible levels
following perfusion through the carbon monoliths. Blood
was pumped directly through the nanoporous monoliths
without causing additional reduction in platelet count or
significant removal of albumin when compared to the
control circuits, although an overall drop in platelet count
occurred in both groups. IL-6 levels were raised in 2 of the
10 clinical samples studied indicating that a more ubiqui-
tous high molecular weight marker is necessary to assess
sorbent efficacy in a small sample pilot study. Further work
is necessary to develop and assess a scaled up device that
can be used in conjunction with a dialysis circuit.
Although, preliminary data suggests a sustained capacity
for protein bound uraemic toxin removal it should be noted
that not all putative uraemic solutes are suitable for
removal by activated carbon adsorption. Molecules with
aromatic rings and a propensity for hydrophobic interac-
tions are adsorbed but electrolytes and highly water soluble
molecules such as urea are not removed to any significant
extent as demonstrated in this and in a previous in vitro
study [32].
It is interesting to note that during the in vitro studies
significant IL-6 monolith adsorption required the presence
of larger nanopores. In contrast some removal of the
albumin bound IS and p-CS occurred in the microporous
monoliths with pores of less than 2 nm only. IL-6 is a 185
amino-acid, pleiotropic protein with a molecular weight
range of 21–26 kDa and a tertiary structure made up of
four alpha helices [36]. The structural dimensions of IL-6
are 5 9 5 9 12.2 nm resulting in no significant adsorption
by microporous carbon. Similarly human serum albumin is
a globular protein with approximate dimensions of
8 9 8 9 3 nm [37] indicating that adsorption of IS and
p-CS as albumin bound complexes by microporous carbons
should not occur since the complex will not fit within the
2 nm wide porous domains. The normal concentration
range of albumin in plasma is around 500–700 lM. We
observed a mean IS concentration of 49 ± 16 lM and a
mean p-CS concentration of 174 ± 17 lM in post dialysis
patient samples. These molecules compete for the same
albumin binding site so that a much larger drop in albumin
would be expected if the whole albumin-IS/p-CS complex
was simply removed by carbon monolith adsorption,
assuming a binding ratio of 1:1. Albumin concentration in
the haemodialysis patient blood samples dropped following
monolith filtration but remained in the normal range
suggesting some adsorption by the monolith but not enough
to explain the almost complete removal of IS and p-CS.
The results of our study suggest that removal is more likely
to occur through disruption of the non-covalent bond
between albumin and these molecules. The pore walls of
activated carbon have high adsorption affinity towards
aromatic substances, such as p-CS and IS, facilitating
dissociation of their complexes with albumin.
The rapid reduction in IS and PCS concentration in the
post-dialysis blood samples suggests different binding
dynamics to that of the in vitro spiked studies using healthy
donor blood. CKD is associated with changes in the con-
centration, tertiary structure and binding capacity of albu-
min. Albumin contains a large number of thiol groups and
acts as a key circulating anti-oxidant through the formation
of disulphide bonds with excess circulating free radicals
[38, 39]. Chronic exposure to oxidative stress increases the
population of highly oxidised forms of albumin inducing
conformational changes and reducing binding and transport
capacity for molecules such as IS and p-CS. The results
suggest a greater propensity for carbon adsorption of
albumin bound molecules from the haemodialysis patient
blood samples due to decreased albumin binding capacity.
However, further work is necessary to highlight the specific
nature of molecular binding to the carbon surface and
changes in the interaction of protein bound toxins with
albumin and nanoporous activated carbons in patients with
CKD5d.
A number of issues surround the introduction of an
adsorbent device into clinical practice including the
potential removal of beneficial substances and the capacity
of the device to maintain sufficient clearance of uraemic
toxins. Previous publications have indicated limited
rebound release of p-CS from tissue into the vascular space
30 min after haemodialysis [40]. Rebound of small water
soluble molecules urea and potassium is known to occur in
CKD in the first hour following haemodialysis and rebound
of cytokines in sepsis associated acute kidney injury occurs
where removal by haemofiltration is matched by further
production and tissue release back into the blood plasma so
that no overall drop in cytokine levels is observed [41]. In
the case of inflammatory mediators it may not be beneficial
to clear them completely from the blood but only to
remove the peak concentrations so that suppression of
excessive inflammatory disregulation occurs. The non-
specificity of activated carbon adsorption is preferable to
single target therapies in view of the spectrum of uraemic
toxins which accumulate in CKD5d. Although there may
be some removal of beneficial molecules in the equivalent
molecular weight range replacement is possible through
normal homeostatic mechanisms. Adsorption tends to cap
only the peak concentrations of dominant plasma proteins
such as albumin and fibrinogen but significantly reduces
J Mater Sci: Mater Med (2014) 25:1589–1597 1595
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the pathophysiologically high levels of uraemic toxins such
as IS and p-CS where homeostatic regulation through renal
excretion has failed. In the current study no significant
reduction in albumin and fibrinogen levels occurred in the
monolith filtration samples compared to the controls,
although the concentration of fibrinogen was low for all
samples.
5 Conclusion
The rising incidence of patients with CKD5 and the
absence of clear data on survival benefit using the current
haemodialysis regime calls for new and innovative
approaches. Positive preliminary data suggests that adsor-
bent systems such as the one described may be used to
augment high molecular weight and protein bound uraemic
toxin removal, reducing chronic inflammatory stimulus and
impacting the poor prognosis for patients with CKD5d.
Acknowledgments All activated carbon beads and monolith sam-
ples were synthesised by MAST CarbonInternational Ltd, Basing-
stoke, UK. This work is independent research funded by the National
Institute for Health Research, UK(Invention for Innovation (i4i),
Product Development Awards, II-FS-0909-13116). The views
expressed in this publication are those of the author(s) and not nec-
essarily those of the NHS, theNational Institute for Health Research
or the Department of Health.
Conflict of interest The authors declare no competing interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A,
Papadomitriou M, Wizemann V, Jacobson S, Czekalski S,
Ronco C, Vanholder R, Membrane Permeability Outcome
(MPO) Study Group. Effect of membrane permeability on
survival of haemodialysis patients. J Am Soc Nephrol.
2009;20:645–54.
2. Eknoyan G, Beck GJ, Cheung AK, Daugirdas J, Greene T, Kusek
JW, Allon M, Delmez JA, Depner TA, Dwyer JT, Levey AS,
Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G,
Schwab SJ, Teehan BP, Toto R. Effect of dialysis dose and
membrane flux in maintenance hemodialysis. N Engl J Med.
2002;347(25):2010–9.
3. Eggers P. Has the incidence of end-stage renal disease in USA and
other countries stabilized? Curr Opin Nephrol Hypertens. 2011;
20(3):241–5.
4. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution
of chronic kidney disease to the global burden of major non-
communicable diseases. Kidney Int. 2011;80(12):1258–70.
5. Lameire N, Jager K, Van Biesen W, De Bacquer D, Vanholder R.
Chronic kidney disease: a European perspective. Kidney Int.
2005;68(S99):S30–8.
6. El Nahas AM, Bello AK. Chronic kidney disease: the global
challenge. Lancet. 2005;365:331–40.
7. Stenvinkel P. Chronic kidney disease: a public health priority and
harbinger of premature cardiovascular disease. J Intern Med.
2010;1365:2796.
8. Silverstein D. Inflammation in chronic kidney disease: role in the
progression of renal and cardiovascular disease. Pediatr Nephrol.
2009;24:1445–52.
9. Fujii H, Nakai K, Fukagawa M. Role of oxidative stress and
indoxyl sulfate in progression of cardiovascular disease in
chronic kidney disease. Ther Apher Dial. 2011;15(2):125–8.
10. Yu H. Progression of chronic renal failure. Arch Intern Med.
2003;163:1417–29.
11. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder
R, Brunet P. Protein-bound toxins—update. Semin Dial. 2009;
22(4):334–9.
12. Carrero JJ, Park S-H, Axelsson J, Lindholm B, Stenvinkel P.
Cytokines, atherogenesis, and hypercatabolism in chronic kidney
disease: a dreadful triad. Semin Dial. 2009;22(4):381–6.
13. Himmelfarb J. Uraemic toxicity, oxidative stress and haemodi-
alysis as renal replacement therapy. Semin Dial. 2009;22(6):
636–43.
14. Glorieux G, Cohen G, Jankowski J, Vanholder R. Platelet/leuko-
cyte activation, inflammation, and uremia. Semin Dial. 2009;22(4):
423–7.
15. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G,
Schepers E, Temmar M, Choukroun G, Vanholder R, Massy ZA.
Free p-cresylsulphate is a predictor of mortality in patients at
different stages of chronic kidney disease. Nephrol Dial Trans-
plant. 2009;25(4):1183–91.
16. Barreto D, Barreto F, Liabeuf S, Temmar M, Lemke H-D, Tri-
bouilloy G, Choukroun G, Vanholder R, Massy ZA. Plasma
interleukin-6 is independently associated with mortality in both
hemodialysis and pre-dialysis patients with chronic kidney dis-
ease. Kidney Int. 2010;77:550–6.
17. Meijers B, De Loor H, Bammens B, Verbeke K, Vanrenterghem
Y, Evenepoel P. P-cresyl sulphate and indoxyl sulphate in he-
modialysis patients. Clin J Am Soc Nephrol. 2009;4:1932–8.
18. Oberg B, McMenamin E, Lucas F, McMonagle E, Morrow J,
Ikizler T, Himmelfarb J. Increased prevalence of oxidant stress
and inflammation in patients with moderate to severe chronic
kidney disease. Kidney Int. 2004;65:1009–16.
19. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterg-
hem Y. Free serum concentrations of protein bound retention
solute p-cresol predict mortality in HD patients. Kidney Int.
2006;69:1081–7.
20. Niwa T. Uremic toxicity of indoxyl sulphate. Nagoya J Med Sci.
2010;72:1–11.
21. Bolati D, Shimizu H, Niwa T. AST-120 ameliorates epithelial-to-
mesenchymal transition and interstitial fibrosis in the kidneys of
chronic kidney disease rats. J Ren Nutr. 2012;22:176–80.
22. Vanholder R, Van Laecke S, Glorieux GG. What is new in ure-
mic toxicity? Pediatr Nephrol. 2008;23:1211–21.
23. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J,
Vanholder R. P-cresyl sulphate, the main in vivo metabolite of p-
cresol, activates leucocyte free radical production. Nephrol Dial
Transplant. 2007;22:592–6.
24. Stadlbauer V, Krisper P, Aigner R, Haditsch B, Jung A, Lackner
C, Stauber RE. Effect of extracorporeal liver support by MARS
and Prometheus on serum cytokines in acute-on-chronic liver
failure. Crit Care. 2006;R169:1–8.
25. Ash S, Sullivan T, Carr D. Sorbent suspensions vs sorbent col-
umns for extracorporeal detoxification in hepatic failure. Ther
Apher Dial. 2006;10(2):145–53.
26. Hagstam KE, Larsson LE, Thysell H. Experimental studies on
charcoal haemoperfusion in phenobarbital intoxication and
1596 J Mater Sci: Mater Med (2014) 25:1589–1597
123
uraemia, including histopathologic findings. Acta Med Scand.
1966;180(5):593–603.
27. Andrade JD, Van Wagenen R, Chen C, Ghavamian M, Volder J,
Kirkham R, Kolff WJ. Coated adsorbents for direct blood per-
fusion II. Trans Am Soc Artif Intern Organs. 1972;18:473–83.
28. Dunea G, Kolff WJ. Clinical experience with the Yatzidis char-
coal artificial kidney. Trans Am Soc Artif Intern Organs.
1965;11:178–82.
29. Chang TM. Semipermeable aqueous microcapsules (‘‘artificial
cells’’): with emphasis on experiments in an extracorporeal shunt
system. Trans Am Soc Artif Intern Organs. 1966;12:13–9.
30. Mikhalovksy S, Sandeman S, Howell C, Phillips G, Nikolaev V.
Ch21: biomedical applications of carbon adsorbents. In: Tascon
JMD, editor. Novel carbon adsorbents. Oxford: Elsevier; 2012.
31. Sandeman SR, Howell CA, Phillips GJ, Davies JG, Lloyd AW,
Mikhalovsky SV, Tennison SR, Rawlinson AP, Kozynchemko
OP. Inflammatory cytokine removal by an activated carbon
device in a flowing system. Biomaterials. 2008;29:1638–44.
32. Sandeman S, Petersson M, Wiezell S, Howell C, Phillips G,
Zheng Y, Tennison S, Mikhalovsky S. Characterising MAST
carbon adsorbents for biological application to kidney disease.
J Biomater Tissue Eng. 2012;2:40–7.
33. Tripisciano C, Kozynchenko OP, Linsberger I, Phillips GJ, Ho-
well CA, Sandeman SR, Tennison S, Mikhalovsky SV, Weber V,
Falkenhagen D. Activation-dependent adsorption of cytokines
and toxins related to liver failure to carbon beads. Biomacro-
molecules. 2011;12(10):3733–40.
34. Sandeman SR, Howell CA, Phillips GJ, Davies JG, Lloyd AW,
Mikhalovsky SV, Tennison SR, Rawlinson AP, Kozynchemko
OP, Owen H, Gaylor J, Rouse J, Courtney JM. Assessing the
in vitro biocompatibility of a novel carbon device for the treat-
ment of sepsis. Biomaterials. 2005;26:7124–31.
35. De Loor H, Meijers B, Meyer T, Bammensa B, Verbekec K,
Dehaend W, Evenepoela P. Sodium octanoate to reverse indoxyl
sulphate and p-cresyl sufate albumin binding in uremic and normal
serum during sample preparation followed by fluorescence liquid
chromatography. J Chromatogr A. 2009;1216:4684–8.
36. Toumpanakis D, Vassilakopoulos T. Molecular mechanisms of
action of Interleukin-6 (IL-6). Pneumon. 2007;20:154–67.
37. Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K.
Crystal structure of human serum albumin at 2.5 A resolution.
Protein Eng. 1999;12(6):439–46.
38. Meijers B, Bammens B, Verbeke K, Evenepoel P. A review of
albumin binding in CKD. Am J Kidney Dis. 2008;51(5):839–50.
39. Oettl K, Stauber R. Physiological and pathological changes in the
redox state of human serum albumin critically influence its
binding properties. Br J Pharmacol. 2007;151:580–90.
40. Martinez A, Recht N, Hostetter T, Meyer T. Removal of p-cresol
sulfate by hemodialysis. J Am Soc Nephrol. 2005;16:3430–6.
41. Mayer N, Rostaing L, Nigier M, Jaafar A, Cointault O, Kamar N,
Conil J, Fourcade O, Lavayssiere L. Kinetics of plasmatic cytokines
and cystatin C during and after hemodialysis in septic shock-relatd
acute renal failure. Crit Care. 2012;14(R115):1–9.
J Mater Sci: Mater Med (2014) 25:1589–1597 1597
123
